# A Phase II Study of SHR-1210 vs Placebo as Consolidation Chemotherapy After Radical Concurrent Chemoradiotherapy in Locally Advanced ESCC

> **NCT03817658** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital of Zhengzhou University** · enrollment: 725 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** SHR-1210
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03817658
- **Lead sponsor:** The First Affiliated Hospital of Zhengzhou University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10
- **Primary completion:** 2020-10
- **Final completion:** 2021-10
- **Target enrollment:** 725 (ESTIMATED)
- **Last updated:** 2019-01-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03817658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03817658, "A Phase II Study of SHR-1210 vs Placebo as Consolidation Chemotherapy After Radical Concurrent Chemoradiotherapy in Locally Advanced ESCC". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03817658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*